DexCom (DXCM) Earns News Sentiment Rating of 0.23
Media coverage about DexCom (NASDAQ:DXCM) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DexCom earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 79 out of 100, meaning that recent news coverage is likely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern’s scoring:
- Official Price Target Objectives For Fiserv, Inc. (FISV), DexCom, Inc. (DXCM) – StockNewsMagazine (stocknewsmagazine.com)
- DexCom, Inc. (DXCM) Upgraded to “Buy” at BidaskClub (americanbankingnews.com)
- DexCom Inc (DXCM) Moving 0.75% in Session – Stock Press Daily (stockpressdaily.com)
- DexCom Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017 at 4:30 p.m. Eastern Time (finance.yahoo.com)
- Baillie Gifford & Company Continues to Hold Stake in Dexcom (DXCM), Dorsey Wright & Associates Stake in Ingredion … – BZ Weekly (bzweekly.com)
A number of equities analysts have commented on DXCM shares. Cowen and Company reiterated an “outperform” rating and issued a $90.00 target price on shares of DexCom in a report on Tuesday, April 18th. BTIG Research lowered DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. William Blair restated an “outperform” rating on shares of DexCom in a research note on Thursday, April 27th. Jefferies Group LLC dropped their target price on DexCom to $91.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. Finally, Canaccord Genuity dropped their target price on DexCom from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 3rd. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. DexCom presently has an average rating of “Buy” and an average price target of $90.44.
Shares of DexCom (NASDAQ DXCM) traded down 1.72% on Friday, hitting $77.33. The stock had a trading volume of 903,940 shares. The firm’s 50-day moving average is $71.34 and its 200-day moving average is $74.18. The company’s market cap is $6.68 billion. DexCom has a one year low of $57.68 and a one year high of $96.38.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. The firm had revenue of $142.30 million for the quarter, compared to the consensus estimate of $143.94 million. On average, analysts expect that DexCom will post ($0.70) EPS for the current fiscal year.
In other DexCom news, insider Terrance H. Gregg sold 15,000 shares of the business’s stock in a transaction on Thursday, April 20th. The stock was sold at an average price of $74.10, for a total transaction of $1,111,500.00. Following the sale, the insider now directly owns 454,559 shares in the company, valued at $33,682,821.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of the business’s stock in a transaction on Monday, April 17th. The stock was sold at an average price of $75.63, for a total value of $756,300.00. Following the sale, the chief executive officer now owns 353,680 shares in the company, valued at $26,748,818.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,613 shares of company stock worth $4,033,532. Company insiders own 1.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/23/somewhat-positive-press-coverage-likely-to-impact-dexcom-dxcm-stock-price-updated.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.